Bristol Myers Squibb stock steadies after autoimmune CAR-T trial pause
Published on 09/01/2026 at 09:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock (ISIN US0897961004) is trading in the mid-$60 range as of August 30, 2026, with investors balancing solid Q2 2026 earnings guidance against fresh safety-driven pauses in autoimmune CAR-T trials.
Per an equity overview dated August 31, 2026, the shares were referenced near $66.58, close to the prior session’s $66.47 U.S. close, and a market capitalization of $136.00 billion underlines the group’s large-cap scale in global pharmaceuticals.
At the same time, the company has voluntarily paused enrollment in autoimmune studies of its experimental CAR-T therapy zolacabtagene autoleucel to review transient inflammatory events, a move that keeps safety squarely in view for investors tracking Bristol Myers Squibb’s cell therapy pipeline.
Shares consolidate in the mid-$60 range
Recent trading data show Bristol Myers Squibb stock quoted at $66.47 during the U.S. session on August 30, 2026, with an intraday range between $66.19 and $67.39, indicating that the price has been consolidating in a tight band around the mid-$60 level rather than breaking out sharply.
An equity snapshot compiled on August 31, 2026 referenced the stock at $66.58 with a market cap of $136.00 billion, implying that the shares were only $0.11 above the prior session’s close and sit 1.4 percent below the recent intraday high of $67.39, a small but concrete gap that frames the short-term trading range.
Complementary quote data from another market portal mention a recent closing price of $63.86 for the New York listing, with the stock easing 1.22 percent at that snapshot and a modest 0.18 percent move in extended trading, underscoring that day-to-day moves have stayed relatively measured even as drug-sector headlines remain active.
Q2 2026 earnings and EPS guidance anchor valuation
Same-day earnings and analyst summaries indicate that Bristol Myers Squibb’s latest reported financials are its Q2 2026 results, which form the current basis for investors’ view of the company’s execution this year.
Coverage aggregating management’s outlook reports that Bristol Myers Squibb has set its fiscal 2026 EPS guidance in a range between $6.75 and $7.00 per share, giving the market a quantified frame for this year’s earnings power and tying valuation directly to that expected profit stream.
Consensus views compiled alongside that guidance center on an EPS projection of $6.95 for fiscal 2026, a figure that sits $0.20 above the lower end of the $6.75 range and $0.05 below the top of the $7.00 range, signaling that analysts broadly expect performance toward the upper half of management’s stated outlook.
Recent overviews further highlight that as of the August 30, 2026 U.S. trading session, Bristol Myers Squibb stock at $66.47 with a market cap near $136.00 billion implies a price-to-earnings multiple in the mid-teens based on the $6.95 fiscal 2026 EPS consensus, aligning the valuation with a moderate-growth, cash-generative big pharma profile rather than a high-multiple speculative biotech.
Historical comparisons from prior years suggest that revenue and profit trends have been shaped by shifts across oncology, immunology and cardiovascular portfolios, but for investors the current focus is explicitly on the Q2 2026 results and the 2026 EPS guidance range as they update the company’s performance trajectory.
Autoimmune CAR-T trial pause adds pipeline risk color
On August 31, 2026, sector reporting highlighted that multiple pharmaceutical companies have paused autoimmune cell therapy trials while reviewing serious inflammatory side effects observed in patients.
In that context, Bristol Myers Squibb has voluntarily paused enrollment in autoimmune trials evaluating its own CAR-T treatment zolacabtagene autoleucel, referred to as zola-cel, in order to review clinical data across the program after detecting transient and reversible inflammatory events during routine safety monitoring.
The company has indicated that the evaluation seeks to understand the nature and implications of these inflammatory reactions and that the aim is to resume testing as quickly as possible once the review is complete, an approach that emphasizes a safety-first stance while still signaling long-term commitment to autoimmune cell therapy.
For investors, the pause means that timelines for pivotal autoimmune indications under the zola-cel program could be reassessed, but the transient and reversible description of the inflammatory events suggests that the issue is being handled as a precautionary risk-management step rather than an outright termination of development.
At the broader sector level, similar pauses by peers in autoimmune cell therapy reinforce the perception that the field carries complex safety challenges, and Bristol Myers Squibb’s move contributes to a narrative in which regulators and companies will likely scrutinize trial designs, monitoring protocols and patient selection more closely in upcoming studies.
Consensus rating and sector backdrop
According to a consensus overview compiled by market data aggregators, Bristol Myers Squibb stock presently carries an aggregated analyst rating described as a moderate buy, coupled with a consensus price target cited at $66.06, placing the target very close to the recent $66.47 spot price and suggesting a relatively limited implied upside from the current level.
The proximity of the $66.06 price target to the actual mid-$60 trading range indicates that, on average, analysts see the shares as fairly valued on current information, with upside potential likely hinging on execution against the 2026 EPS guidance and resolution of regulatory and clinical questions in the pipeline.
Sector commentary covering the broader drug industry notes that big pharma companies as a group have experienced a comeback phase, with some names exceeding expectations and others grappling with patent cliffs and shifting product mix; in this environment, Bristol Myers Squibb’s mid-teens valuation and moderate buy stance position it as a balanced play rather than a momentum outlier.
For portfolio managers, the combination of a consensus EPS of $6.95 in fiscal 2026, a stock price in the mid-$60 range and a market cap around $136.00 billion provides a clear numeric basis for comparing Bristol Myers Squibb against other large pharmaceutical issuers competing in oncology, immunology and cardiovascular disease.
Camzyos highlights Bristol Myers Squibb’s cardiovascular franchise
Beyond the autoimmune CAR-T narrative, Bristol Myers Squibb has been advancing Camzyos, its targeted therapy for obstructive hypertrophic cardiomyopathy, as a key asset in its cardiovascular portfolio.
Recent conference coverage has discussed long-term and real-world data for Camzyos presented at a major cardiology congress, reflecting the company’s effort to demonstrate durable efficacy and safety in a chronic heart condition where symptom burden and quality of life are central clinical outcomes.
Camzyos is designed to modulate cardiac muscle contractility in patients with hypertrophic cardiomyopathy, and real-world data can help physicians understand how trial results translate into everyday practice, an important factor in broadening adoption and sustaining revenue contributions from the product.
For Bristol Myers Squibb, Camzyos represents part of a diversified pipeline and product mix that spans heart disease, cancer and immunology, and strong long-term data at cardiology meetings support the strategic goal of growing the cardiovascular segment in tandem with oncology and immunology franchises.
Stock level and investor takeaway
As of the August 30, 2026 U.S. trading session, Bristol Myers Squibb stock on the NYSE closed at $66.47, with intraday trading between $66.19 and $67.39, and recent overviews on August 31, 2026 referenced the shares near $66.58, underlining the stock’s current consolidation in the mid-$60 band.
With fiscal 2026 EPS guidance in a $6.75 to $7.00 range and consensus clustered at $6.95, the market is evaluating whether steady earnings delivery and resolution of autoimmune CAR-T safety questions can support a rerating, or whether the existing mid-teens multiple and consensus price target near $66.06 already capture the foreseeable upside.
Read more
Investor Relations
Fact box
Company: Bristol Myers Squibb Co.
ISIN: US0897961004
Ticker: BMY
Exchange: NYSE
Price (as of August 30, 2026, 3:59 p.m. ET): $66.47 USD
Market cap: $135.98 billion (as of August 30, 2026)
Sector / Industry: Pharmaceuticals / Biotechnology
Index membership: S&P 500
